Here are the 10-Q quarterly reports from Anebulo Pharmac Inc (ANEB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANEB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANEB filings page.
Anebulo Pharmaceuticals, Inc. reported a net loss of $1.999 million for the quarter and $4.158 million for the six months ended December 31, 2025, improving from prior-year losses. Operating expenses fell slightly to $2.620 million for the quarter, as lower R&D was partly offset by higher going‑private related G&A costs.
Cash and cash equivalents were $9.0 million, with total assets of $9.4 million and stockholders’ equity of $7.9 million at December 31, 2025. Management believes cash plus a $3.0 million loan facility will fund operations for at least 12 months. The company continues to advance selonabant, including an ongoing single ascending dose IV study supported by an up to $1.9 million NIH/NIDA grant.
Anebulo is executing a going‑private strategy. It completed a tender offer repurchasing 300,000 shares at $3.50 per share, about 0.73% of shares outstanding as of January 26, 2026, and has announced plans to voluntarily delist from Nasdaq and deregister its common stock, which will end SEC periodic reporting.
Anebulo Pharmaceuticals (ANEB) reported Q1 FY2026 results with a net loss of $2,158,354 as it advances selonabant for cannabis-induced toxicity. Operating expenses were $2,260,260, with research and development at $809,991 (lower due to timing of studies) and general and administrative at $1,450,269 (higher from professional fees related to a potential going‑private transaction). Other income, net, was $101,906, aided by interest income.
Cash and cash equivalents were $10,354,773 as of September 30, 2025, and management believes this, along with availability under a $3,000,000 Loan Agreement accruing at 0.25% per annum, will fund operations for at least 12 months. No amounts were drawn under the facility. Net cash used in operating activities was $1,273,076 for the quarter.
The company received a notice of award on September 2, 2025 for Year 2 of its NIDA grant (approximately $1.0 million) to support IV selonabant development. Shares outstanding were 41,084,731 as of September 30, 2025. A Special Committee continues to evaluate strategic alternatives, including a proposed reverse stock split within a 1‑for‑2,500 to 1‑for‑7,500 range as part of a potential going‑private process.